Laboratoire d'Hématologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Interface de Recherche Fondamentale et Appliquée en Cancérologie, INSERM U1113, Strasbourg, France.
J Clin Lab Anal. 2023 Apr;37(7):e24884. doi: 10.1002/jcla.24884. Epub 2023 Apr 23.
Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin therapy associated with thrombosis that requires a quick diagnosis. Therefore, laboratory assays must provide an accurate and swift answer. This work aims to evaluate the performances of an ELISA assay, especially when combined with 4T risk score, and a functional assay.
Data were collected for 894 patients treated by heparin who underwent anticoagulant switch because of HIT suspicion and were examined by a multidisciplinary expert team who confirmed or ruled out HIT diagnosis. All patients were tested for anti-PF4 IgG with Asserachrom HPIA IgG (ELISA), and 307 were tested with a platelet aggregation test done on platelet-rich plasma (PRP-PAT). The 4T risk score was available for 607 of them.
HIT was diagnosed in 232 patients. 4T risk score had a 94.2% negative predictive value (NPV) for risk scores ≤3 and 77.3% for risk scores ≤5. The sensitivity of ELISA was 90.9%, its specificity 79.0%, and its NPV 96.1%. When combined with 4T risk score, its NPV reached 100% and 97% for risk scores ≤3 and ≤5, respectively. PRP-PAT sensitivity was 70.4%, and its specificity was 92.3%. Combination of ELISA and PRP-PAT had a 0.7% false-negative rate.
This study shows that ELISA can rule out HIT with an excellent NPV, especially when combined with the 4T risk score. Nonetheless, it has low specificity; hence, it needs to be associated with a functional assay.
肝素诱导的血小板减少症(HIT)是肝素治疗相关血栓形成的严重并发症,需要快速诊断。因此,实验室检测必须提供准确和快速的答案。本研究旨在评估 ELISA 检测方法的性能,特别是当与 4T 风险评分和功能检测联合使用时。
共收集了 894 例因怀疑 HIT 而接受抗凝药物转换治疗的肝素治疗患者的数据。这些患者均由多学科专家团队进行检查,以确认或排除 HIT 诊断。所有患者均接受 Asserachrom HPIA IgG(ELISA)检测抗 PF4 IgG,其中 307 例接受血小板富血浆(PRP-PAT)血小板聚集试验检测。其中 607 例患者可获得 4T 风险评分。
232 例患者被诊断为 HIT。4T 风险评分≤3 时的阴性预测值(NPV)为 94.2%,评分≤5 时的 NPV 为 77.3%。ELISA 的灵敏度为 90.9%,特异性为 79.0%,NPV 为 96.1%。当与 4T 风险评分联合使用时,评分≤3 和≤5 时的 NPV 分别达到 100%和 97%。PRP-PAT 的灵敏度为 70.4%,特异性为 92.3%。ELISA 和 PRP-PAT 联合检测的假阴性率为 0.7%。
本研究表明,ELISA 检测可排除 HIT,具有极好的 NPV,尤其是与 4T 风险评分联合使用时。然而,其特异性较低;因此,需要与功能检测联合使用。